Table 5 SIR, RR and AER for subsequent primary malignant neoplasms (SPNs) of the tongue by different factors among all cancer survivors in the PanCareSurFup cohort.

From: Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study

SPN on tongue

Level

Obs (%)

Exp

SIR (95% CI)

RR (95%CI)

AER (95% CI)

 

Overall

38 (100%)

6.4

5.9 (4.7–7.4)

–

2.5 (1.9–3.3)

Sexa

Male

24 (63%)

4.2

5.7 (3.8–8.5)

1.0 (ref)

2.9 (1.8–4.8)

Female

14 (37%)

2.2

6.5 (3.8–10.9)

0.9 (0.4–1.7)

2.0 (1.1–3.7)

pheterogeneity

  

0.70

0.65

0.34

Type of childhood cancera

Leukaemia

17 (45%)

0.7

25.7 (16.0–41.4)

1.4 (0.5–3.9)

6.3 (3.9–10.4)

Hodgkin lymphoma

2 (5%)

0.7

3.1 (0.8–12.2)

0.3 (0.1–1.4)

1.4 (0.2–10.8)

Non-HL

0 (0%)

0.4

–

–

–

CNS tumour

0 (0%)

1.5

–

–

–

Neuroblastoma

1 (3%)

0.2

5.2 (0.7–36.8)

0.6 (0.1–5.0)

1.3 (0.1–14.8)

Retinoblastoma

1 (3%)

0.4

2.6 (0.4–18.3)

0.5 (0.0–4.3)

0.9 (0.0–21.4)

Wilms tumour

2 (5%)

0.4

5.0 (1.3–20.0)

0.5 (0.1–2.9)

1.5 (0.3–8.3)

Bone sarcoma

6 (16%)

0.4

14.3 (6.4–31.7)

1.4 (0.4–4.6)

9.8 (4.2–23.2)

Soft tissue sarcoma

5 (13%)

0.6

8.7 (3.6–21.0)

1.0 (ref))

4.8 (1.8–12.9)

Other

4 (11%)

1.1

3.7 (1.4–9.8)

0.4 (0.1–1.6)

1.6 (0.4–6.0)

pheterogeneity

  

<0.001

<0.001

<0.001

Decade of childhood cancer diagnosisa

<1970

5 (13%)

3.4

1.5 (0.6–3.5)

1.0 (ref)

0.5 (0.0–8.3)

1970–1979

13 (34%)

1.7

7.4 (4.3–12.8)

2.6 (0.8–8.8)

3.2 (1.7–6.0)

1980–1989

16 (42%)

1.0

16.5 (10.1–27.0)

3.7 (0.9–14.9)

3.8 (2.2–6.3)

1990–2008

4 (11%)

0.2

16.0 (6.0–42.6)

2.2 (0.4–12.9)

1.9 (0.7–5.3)

ptrend

  

<0.001

0.35

0.07

Age at childhood cancer (years)a

0–3

9 (24%)

1.4

6.6 (3.4–12.7)

1.0 (ref)

1.7 (0.8–3.8)

4–7

6 (16%)

1.1

5.4 (2.4–12.1)

0.9 (0.3-2.6)

1.8 (0.7-4.7)

8–11

13 (34%)

1.3

9.8 (5.7–17.0)

2.3 (0.8–6.8)

5.6 (3.0–10.2)

12–21

10 (26%)

2.6

3.8 (2.1–7.1)

1.1 (0.3–4.5)

2.2 (0.9–5.0)

ptrend

  

0.36

0.65

0.30

Attained age (years)a

<20

2 (5%)

0.1

35.6 (8.9–142.3)

1.0 (ref)

0.5 (0.1–2.0)

20–29

14 (37%)

0.7

20.8 (12.3–35.1)

0.6 (0.1–2.8)

3.2 (1.8–5.5)

30–39

11 (29%)

1.3

8.8 (4.9–15.9)

0.3 (0.1–1.4)

3.7 (1.9–7.2)

40–49

7 (18%)

1.9

3.6 (1.7–7.6)

0.2 (0.0–1.0)

4.2 (1.5–11.7)

50+

4 (11%)

2.5

1.6 (0.6–4.3)

0.2 (0.0–1.2)

2.9 (0.2–38.1)

ptrend

  

<0.001

0.01

0.003

Time since 5-year survival (years)b

0–9

7 (18%)

0.4

20.0 (9.5–41.9)

1.0 (ref)

1.2 (0.5–2.6)

10–19

12 (32%)

0.9

13.0 (7.4–22.9)

0.5 (0.2–1.4)

3.0 (1.6–5.5)

20–29

10 (26%)

1.6

6.2 (3.3–11.5)

0.3 (0.1–0.9)

3.9 (1.9–8.3)

30+

9 (24%)

3.5

2.6 (1.3–4.9)

0.3 (0.1–1.2)

4.8 (1.6–13.9)

ptrend

  

<0.001

0.07

0.02

Radiotherapy for childhood cancerc,d

Yes

18 (64%)

2.9

6.3 (4.0–10.0)

1.0 (0.4–2.4)

3.2 (1.9–5.6)

No

8 (29%)

1.4

5.7 (2.8–11.4)

1.0 (ref)

2.5 (1.1–5.8)

Unknown

2 (7%)

–

–

–

–

pheterogeneity

  

0.80

0.92

0.62

Chemotherapy for childhood cancerc,d

Yes

24 (86%)

1.5

15.9 (10.6–23.7)

5.6 (1.0–31.2)

5.0 (3.3–7.7)

No

2 (7%)

2.6

0.8 (0.2–3.1)

1.0 (ref)

–

Unknown

2 (7%)

–

–

–

–

pheterogeneity

  

<0.001

0.03

<0.001

  1. Pyrs person-years, Obs observed, Exp expected, SIR standardised incidence ratio, RR relative risk, AER absolute excess risks, HL Hodgkin lymphoma.
  2. aRRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and attained age.
  3. bRRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and follow-up time.
  4. cRRs were derived from a model including sex, country, age at childhood diagnosis, attained age and treatment.
  5. dExcluded Nordic countries (Denmark, Sweden, Norway, Finland, Iceland) and Italy population-based data because of lack of treatment data.
Back to article page